Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. It also sells and rents HME devices, such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment. In addition, the company provides neuromuscular care and oxygen therapy services; and sleep apnea management which provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, it offers in-home sleep apnea testing services; and breast pumps and related lactation equipment and supplies, including fulfillment and support services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.…
Viemed Healthcare Q3 Earnings Call Highlights
Viemed Healthcare (NASDAQ: VMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,490 employees.
The shares were at 8.520 USD on 20 November 2026, up 36.1% over 52 weeks. Its 52-week range is 6.180 USD to 12.61 USD: the price is 32.4% below the high and 37.9% above the low.
At a market capitalisation of 322.85M USD, it trades at 22.4 times trailing earnings and 21.3 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a discount of 12% for VMD.
Viemed Healthcare reports return on equity of 10.6%, an operating margin of 8.4% and revenue up 12.2% year over year.
It holds more cash than debt, a net cash position of 393.00K USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Hold; their mean price target of 12.00 USD is 40.8% above the current price. The next earnings report is expected on 3 March 2027.